An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

NCT03769168 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Psoriatic Arthritis
Enthesitis Related Arthritis

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals